Nova Patents
PL3385284T3

Antibodies to quetiapine haptens and use thereof

Abstract

This record has no abstract on file.

Term

6.9 yearsto projected expiry

Projected expiry 20 August 2033, counted from filing; an application has no term until it is granted.

  1. Priority
  2. Filed
  3. Published
  4. Today
  5. Projected expiry

37 members in 11 offices

This recordMember, by publication datePriority claim1 more office is in the list below

Priority claims13

Priority claims
DocumentOfficeKindDate
201261691598United States of AmericaP
201261691598United States of AmericaP
13830990European Patent Office (EPO)A
13830990European Patent Office (EPO)A
18157667European Patent Office (EPO)A
2013055830United States of AmericaW
2013055830United States of AmericaW
181576679–––
201261691598P–––
EP20130830990–––
EP20180157667–––
US201261691598P–––
WO2013US55830–––

Members37

Family members, oldest first
DocumentOfficeKind
CA2882597A1CanadaA1
US2014057305A1United States of AmericaA1
WO2014031665A1World Intellectual Property Organization (WIPO)A1
AU2013305904A1AustraliaA1
CN104736564AChinaA
EP2888286A1European Patent Office (EPO)A1
JP2015529203AJapanA
EP2888286A4European Patent Office (EPO)A4
HK1211959A1Hong Kong, ChinaA1
AU2013305904B2AustraliaB2
AU2017261579A1AustraliaA1
US9850318B2United States of AmericaB2
EP2888286B1European Patent Office (EPO)B1
US2018105606A1United States of AmericaA1
ES2664952T3SpainT3
PT2888286TPortugalT
PL2888286T3PolandT3
EP3385284A1European Patent Office (EPO)A1
JP6450314B2JapanB2
CN104736564BChinaB
JP2019073513AJapanA
CN110054693AChinaA
US10465013B2United States of AmericaB2
AU2017261579B2AustraliaB2
JP6637580B2JapanB2
US2020040107A1United States of AmericaA1
EP3385284B1European Patent Office (EPO)B1
CA2882597CCanadaC
PT3385284TPortugalT
EP3663317A1European Patent Office (EPO)A1
PL3385284T3This recordPolandT3
ES2788716T3SpainT3
US2021017294A9United States of AmericaA9
EP3663317B1European Patent Office (EPO)B1
PT3663317TPortugalT
ES2935460T3SpainT3
PL3663317T3PolandT3